Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Results 41 - 41 of 41 : « Previous 1 2 3

Recs

6
Member Avatar unguja64 (31.32) Submitted: 8/24/2006 8:03:32 PM : Outperform Start Price: $2.48 HALO Score: +226.75

The main product is very successfully used in IVF (test tube babies technology) and is being tried in a number of cancer treatments as an adjuvant. Big market potential probable buy-out target.

Report this Post 1 Comment | Reply | Permalink
Results 41 - 41 of 41 : « Previous 1 2 3

Featured Broker Partners


Advertisement